Developer docs
API playgroundTry for free, no card

Search company profiles

Koios Medical

Full company profile

uuid0000loi

Namestring
Koios Medical
Legal namestring
Koios Medical, Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Koios Medical, Inc. (formerly Clearview Diagnostics, founded 2011, headquartered in New York with a Chicago office) develops FDA-cleared and CE-marked AI-powered clinical decision support software for ultrasound-based cancer diagnosis. Its flagship products, Koios DS Breast and Koios DS Thyroid (marketed under the Smart Ultrasound® umbrella), use an ensemble of deep learning algorithms trained on a proprietary dataset of more than 500,000 ultrasound images contributed by 48+ research sites worldwide. The software analyzes over 17,000 features per image to classify lesions in real time, align outputs to BI-RADS or TI-RADS/ATA categories, and auto-populate diagnostic reports, with documented outcomes including up to 49% reduction in interpretation time, 20–30% fewer benign biopsies, and improved cancer detection rates.

The company distributes through a hybrid model combining OEM-embedded integration with Philips (EPIQ Elite and Affiniti via the Elevate Plus upgrade) and GE Healthcare (LOGIQ E10), vendor-neutral deployment through PACS workstations and the Harrison.ai Open Platform ecosystem, and direct enterprise sales to hospital systems, academic medical centers, and high-volume radiology practices (500+ installation sites). Revenue comes from volume-based annual subscriptions and billable CPT-coded procedures, following the company's Medicare reimbursement milestone. Strategic capital is led by Mitsui & Co. via its healthcare subsidiary MBK Healthcare Management, aligned with IHH Healthcare Berhad's 80-hospital network to support global expansion.

The team is small (early-30s headcount as of 2019), founder-led by CEO Chad McClennan and CFO/COO Graham Anderson, with William Hulbert as VP of Product Development. The company holds seven US patents plus patents in Australia, China, Japan, and the UK, and is pursuing regulatory clearances and clinical studies to broaden indications.

Short descriptiontext

Koios Medical develops FDA-cleared AI clinical decision support software (Koios DS Breast and Thyroid) that analyzes ultrasound images to help radiologists detect breast and thyroid cancer more accurately, sold to hospital systems and embedded in Philips and GE ultrasound platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical decision support, ultrasound AI software, breast cancer diagnosis, thyroid cancer detection, medical imaging AI
Industry6 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAF
Radiology Reporting, Dictation & Structured Reporting
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
NAICS code2 codes
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Medical Equipment and Supplies Manufacturing3391
Product category
AI Clinical Decision Support Software for Medical Imaging
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software License (Annual/Subscription)
TypeSubscription Recurring
Description

Pricing based on annual diagnostic exam volume; provides software license for unlimited use by entire physician and technologist staff at a facility. This is a recurring subscription model.

koiosmedical.com
2Billable Procedure (CPT Codes)
TypeSubscription Recurring
Description

Koios DS is a billable procedure with assigned CPT codes, allowing healthcare providers to seek reimbursement for AI-assisted diagnostic services. The company has achieved reimbursement milestones alongside other notable radiology AI companies.

ventrahealth.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Volume-based annual licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing based on annual diagnostic exam volume. Unlimited use by entire physician and technologist staff at the licensed facility. CPT codes available for billing.

koiosmedical.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Smart Ultrasound
Description

AI-powered software technology platform for breast and thyroid cancer diagnosis using ultrasound imaging, providing clinical decision support for radiologists.

koiosmedical.com
+3 more records
Core offering1 text field

Koios Medical develops and sells Koios DS, an FDA-cleared and CE-marked AI-powered clinical decision support software for breast and thyroid cancer diagnosis using ultrasound images. The software analyzes over 17,000 features per image using ensemble deep learning algorithms trained on more than 500,000 proprietary ultrasound images, aligning outputs to BI-RADS (breast) and TI-RADS/ATA (thyroid) standards. The product is licensed to radiologists, hospitals, and radiology practices through annual subscription agreements and is also embedded directly into Philips and GE Healthcare ultrasound systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • Up to 20-30% reduction in benign biopsies
+7 more records
Product and service3 records
1Koios DS Breast
CategoryAI Clinical Decision Support Software - Breast Imaging
Description

FDA-cleared and CE-marked AI-powered clinical decision support software for breast cancer diagnosis using ultrasound images. Trained on over 2 million proprietary ultrasound images and analyzes more than 17,000 features per image using ensemble deep learning algorithms. Classifies breast lesions and aligns to BI-RADS categories, providing real-time malignancy risk assessment to radiologists. Licensed on an annual subscription basis per facility with unlimited use by all physicians and technologists.

2Koios DS Thyroid
CategoryAI Clinical Decision Support Software - Thyroid Imaging
Description

AI-powered clinical decision support software for thyroid cancer diagnosis using ultrasound images. Analyzes over 17,000 features per image using proprietary deep learning algorithms to classify thyroid nodules and dynamically calculate malignancy risk aligned to TI-RADS or ATA reporting standards. Designed for endocrinologists and physicians performing thyroid ultrasound examinations. Licensed per facility with unlimited use by staff.

3Koios AI Breast Lesion and Thyroid Nodule Classification (On-Cart)
CategoryAI Clinical Decision Support Software - OEM Embedded Integration
Description

Real-time on-cart AI decision support for breast lesion and thyroid nodule classification during ultrasound exams, available through Philips' Elevate Plus integration on EPIQ Elite and Affiniti systems. Enables radiologists to receive AI-assisted classification directly on the ultrasound cart during examinations, reducing interpretation time and supporting workflow efficiency.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-02
Description

Philips integrated Koios AI decision support into its Elevate Plus software upgrade for EPIQ Elite and Affiniti ultrasound systems. Koios provides real-time breast lesion and thyroid nodule classification during ultrasound exams. This is the first on-cart integration, previously only available off-cart. The partnership reinforces Philips's leadership in AI-powered ultrasound.

2Harrison.ai
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-05-05
Description

Koios was added to Harrison.ai's Open Platform ecosystem alongside AIRAmed, Lunit, and Nanox AI. The platform operates on open architecture with zero mark-ups, allowing healthcare providers to access AI solutions through vendor-neutral integration with existing PACS, RIS, and EHR systems. Harrison.ai has deployments at over 1,000 sites including 40+ NHS Trusts and serves half of Australian radiologists.

mpo-mag.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2016-10-01
Description

Collaborative research partnership for AI tool development for breast cancer diagnosis using low-cost, portable ultrasound imaging devices. This project was funded by a $4 million NIH/NCI grant and aimed to improve breast cancer detection in underserved populations.

Strategic tierCoreTypeTechnology or Integration
Description

Koios DS Breast 2.0 is available connected to PACS and/or directly on GE Healthcare's LOGIQ E10 ultrasound system. This OEM partnership embeds Koios AI into GE's premium flagship ultrasound platform, making AI decision support available to GE Healthcare's extensive customer base.

Strategic tierStrategicTypeTechnology or Integration
Description

As a GE Health Cloud Innovation Challenge winner, Koios was among the first ISVs to host its healthcare application on GE Healthcare's secure, scalable and connected cloud platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Korea-based AI medical imaging company with FDA-cleared breast cancer detection products (Lunit INSIGHT MMG and DBT) and an ultrasound AI line. Closest direct competitor to Koios in breast cancer imaging AI; also a fellow member of the Harrison.ai open platform ecosystem.

TypeDirect peer
Description

Provides AI-based breast cancer detection and risk-stratification software (ProFound AI) used in mammography and DBT workflows. Direct competitor to Koios in AI-assisted breast imaging, with overlapping radiologist and breast-imaging specialist customer base.

TypeDirect peer
Description

Breast imaging analytics and AI software for density assessment, risk evaluation, and quality assurance. Comparable to Koios in its breast-imaging focus and SaaS/subscription delivery to hospital and imaging-center customers.

TypeDirect peer
Description

Developer of Transpara AI decision-support software for breast imaging (mammography, DBT, ultrasound). Closely comparable product category (AI breast lesion classification) and OEM/channel partnership strategy.

TypeDirect peer
Description

French company behind MammoScreen 2.x, an FDA-cleared AI for mammography triage and detection. Comparable AI radiology product, similar customer segments (breast radiologists), and overlapping reimbursement pathway.

TypeBroad incumbent
Description

Broader-scope clinical AI platform covering CT, X-ray, and other modalities with hospital-wide workflow integration. A broader incumbent in radiology AI rather than a breast/ultrasound specialist, but increasingly competing for the same enterprise imaging budgets.

TypeDirect peer
Description

AI clinical decision support and workflow company with FDA-cleared products and Medicare reimbursement for stroke imaging. Peer in the radiology-AI reimbursement cohort alongside Koios, with similar SaaS-to-hospital GTM.

TypeDirect peer
Description

AI-driven cardiovascular diagnostics with Medicare reimbursement. Frequently cited alongside Koios in the radiology AI reimbursement cohort; comparable regulatory and reimbursement milestones and similar SaaS-plus-imaging economics.

TypeBroad incumbent
Description

Major women's health imaging incumbent (mammography, ultrasound) with growing AI investments (e.g., Genius AI for DBT). Both a potential partner and competitor to Koios in breast imaging decision support, with substantially larger sales reach.

TypeBroad incumbent
Description

Koios's largest OEM partner via the Elevate Plus integration on EPIQ Elite and Affiniti ultrasound. Also a broad incumbent in ultrasound imaging that could in-source competing AI capabilities over time, making it both a channel partner and a strategic risk.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Koios Medical

AI Clinical Decision Support Software for Medical Imagingkoiosmedical.com

Koios Medical develops FDA-cleared AI clinical decision support software (Koios DS Breast and Thyroid) that analyzes ultrasound images to help radiologists detect breast and thyroid cancer more accurately, sold to hospital systems and embedded in Philips and GE ultrasound platforms.

What Koios Medical does

Koios Medical, Inc. (formerly Clearview Diagnostics, founded 2011, headquartered in New York with a Chicago office) develops FDA-cleared and CE-marked AI-powered clinical decision support software for ultrasound-based cancer diagnosis. Its flagship products, Koios DS Breast and Koios DS Thyroid (marketed under the Smart Ultrasound® umbrella), use an ensemble of deep learning algorithms trained on a proprietary dataset of more than 500,000 ultrasound images contributed by 48+ research sites worldwide. The software analyzes over 17,000 features per image to classify lesions in real time, align outputs to BI-RADS or TI-RADS/ATA categories, and auto-populate diagnostic reports, with documented outcomes including up to 49% reduction in interpretation time, 20–30% fewer benign biopsies, and improved cancer detection rates.

The company distributes through a hybrid model combining OEM-embedded integration with Philips (EPIQ Elite and Affiniti via the Elevate Plus upgrade) and GE Healthcare (LOGIQ E10), vendor-neutral deployment through PACS workstations and the Harrison.ai Open Platform ecosystem, and direct enterprise sales to hospital systems, academic medical centers, and high-volume radiology practices (500+ installation sites). Revenue comes from volume-based annual subscriptions and billable CPT-coded procedures, following the company's Medicare reimbursement milestone. Strategic capital is led by Mitsui & Co. via its healthcare subsidiary MBK Healthcare Management, aligned with IHH Healthcare Berhad's 80-hospital network to support global expansion.

The team is small (early-30s headcount as of 2019), founder-led by CEO Chad McClennan and CFO/COO Graham Anderson, with William Hulbert as VP of Product Development. The company holds seven US patents plus patents in Australia, China, Japan, and the UK, and is pursuing regulatory clearances and clinical studies to broaden indications.

Koios Medical firmographics

Firmographics
Name
Koios Medical
Legal name
Koios Medical, Inc.
Website
https://koiosmedical.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Koios Medical develops FDA-cleared AI clinical decision support software (Koios DS Breast and Thyroid) that analyzes ultrasound images to help radiologists detect breast and thyroid cancer more accurately, sold to hospital systems and embedded in Philips and GE ultrasound platforms.
Ownership category
akta.pro rank

Koios Medical industry classification

Industry
Product category
AI Clinical Decision Support Software for Medical Imaging
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Medical Equipment and Supplies Manufacturing (3391)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAHABAI
Imaging Informatics & Workflow (PACS/RIS/VNA)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACALAF
Radiology Reporting, Dictation & Structured Reporting
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability

Keywords

  • Clinical decision support
  • Ultrasound AI software
  • Breast cancer diagnosis
  • Thyroid cancer detection
  • Medical imaging AI

Where Koios Medical is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Koios Medical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software License (Annual/Subscription): Pricing based on annual diagnostic exam volume; provides software license for unlimited use by entire physician and technologist staff at a facility. This is a recurring subscription model.
  2. Billable Procedure (CPT Codes): Koios DS is a billable procedure with assigned CPT codes, allowing healthcare providers to seek reimbursement for AI-assisted diagnostic services. The company has achieved reimbursement milestones alongside other notable radiology AI companies.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualVolume-based annual licensing

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Koios Medical product offering

Product offering

Core offering

Koios Medical develops and sells Koios DS, an FDA-cleared and CE-marked AI-powered clinical decision support software for breast and thyroid cancer diagnosis using ultrasound images. The software analyzes over 17,000 features per image using ensemble deep learning algorithms trained on more than 500,000 proprietary ultrasound images, aligning outputs to BI-RADS (breast) and TI-RADS/ATA (thyroid) standards. The product is licensed to radiologists, hospitals, and radiology practices through annual subscription agreements and is also embedded directly into Philips and GE Healthcare ultrasound systems.

Differentiator

Problem solved

Functional benefit

Brands

  • Smart Ultrasound: AI-powered software technology platform for breast and thyroid cancer diagnosis using ultrasound imaging, providing clinical decision support for radiologists.
  • Koios DS
  • Koios DS Breast
  • Koios DS Thyroid

Products and services

  • Koios DS Breast FDA-cleared and CE-marked AI-powered clinical decision support software for breast cancer diagnosis using ultrasound images. Trained on over 2 million proprietary ultrasound images and analyzes more than 17,000 features per image using ensemble deep learning algorithms. Classifies breast lesions and aligns to BI-RADS categories, providing real-time malignancy risk assessment to radiologists. Licensed on an annual subscription basis per facility with unlimited use by all physicians and technologists.
  • Koios DS Thyroid AI-powered clinical decision support software for thyroid cancer diagnosis using ultrasound images. Analyzes over 17,000 features per image using proprietary deep learning algorithms to classify thyroid nodules and dynamically calculate malignancy risk aligned to TI-RADS or ATA reporting standards. Designed for endocrinologists and physicians performing thyroid ultrasound examinations. Licensed per facility with unlimited use by staff.
  • Koios AI Breast Lesion and Thyroid Nodule Classification (On-Cart) Real-time on-cart AI decision support for breast lesion and thyroid nodule classification during ultrasound exams, available through Philips' Elevate Plus integration on EPIQ Elite and Affiniti systems. Enables radiologists to receive AI-assisted classification directly on the ultrasound cart during examinations, reducing interpretation time and supporting workflow efficiency.

Quantifiable outcome

  • Up to 20-30% reduction in benign biopsies
  • +7 more outcomes

Companies that use Koios Medical

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Koios Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability3 records

Feature5 records

Koios Medical partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and strategic.

  • PhilipscoreTechnology or Integration · 2 June 2026Philips integrated Koios AI decision support into its Elevate Plus software upgrade for EPIQ Elite and Affiniti ultrasound systems. Koios provides real-time breast lesion and thyroid nodule classification during ultrasound exams. This is the first on-cart integration, previously only available off-cart. The partnership reinforces Philips's leadership in AI-powered ultrasound.
  • Harrison.aistrategicTechnology or Integration · 5 May 2026Koios was added to Harrison.ai's Open Platform ecosystem alongside AIRAmed, Lunit, and Nanox AI. The platform operates on open architecture with zero mark-ups, allowing healthcare providers to access AI solutions through vendor-neutral integration with existing PACS, RIS, and EHR systems. Harrison.ai has deployments at over 1,000 sites including 40+ NHS Trusts and serves half of Australian radiologists.
  • Dr. Susan Love Research FoundationstrategicStrategic or Co-development Partner · 1 October 2016Collaborative research partnership for AI tool development for breast cancer diagnosis using low-cost, portable ultrasound imaging devices. This project was funded by a $4 million NIH/NCI grant and aimed to improve breast cancer detection in underserved populations.
  • GE HealthcarecoreTechnology or IntegrationKoios DS Breast 2.0 is available connected to PACS and/or directly on GE Healthcare's LOGIQ E10 ultrasound system. This OEM partnership embeds Koios AI into GE's premium flagship ultrasound platform, making AI decision support available to GE Healthcare's extensive customer base.
  • GE Healthcare (GE Health Cloud)strategicTechnology or IntegrationAs a GE Health Cloud Innovation Challenge winner, Koios was among the first ISVs to host its healthcare application on GE Healthcare's secure, scalable and connected cloud platform.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Koios Medical competitors and assessment

Company assessment

Direct peers

  • Lunit: Korea-based AI medical imaging company with FDA-cleared breast cancer detection products (Lunit INSIGHT MMG and DBT) and an ultrasound AI line. Closest direct competitor to Koios in breast cancer imaging AI; also a fellow member of the Harrison.ai open platform ecosystem.
  • iCAD: Provides AI-based breast cancer detection and risk-stratification software (ProFound AI) used in mammography and DBT workflows. Direct competitor to Koios in AI-assisted breast imaging, with overlapping radiologist and breast-imaging specialist customer base.
  • Volpara Health Technologies: Breast imaging analytics and AI software for density assessment, risk evaluation, and quality assurance. Comparable to Koios in its breast-imaging focus and SaaS/subscription delivery to hospital and imaging-center customers.
  • ScreenPoint Medical: Developer of Transpara AI decision-support software for breast imaging (mammography, DBT, ultrasound). Closely comparable product category (AI breast lesion classification) and OEM/channel partnership strategy.
  • Therapixel: French company behind MammoScreen 2.x, an FDA-cleared AI for mammography triage and detection. Comparable AI radiology product, similar customer segments (breast radiologists), and overlapping reimbursement pathway.
  • Viz.ai: AI clinical decision support and workflow company with FDA-cleared products and Medicare reimbursement for stroke imaging. Peer in the radiology-AI reimbursement cohort alongside Koios, with similar SaaS-to-hospital GTM.
  • HeartFlow: AI-driven cardiovascular diagnostics with Medicare reimbursement. Frequently cited alongside Koios in the radiology AI reimbursement cohort; comparable regulatory and reimbursement milestones and similar SaaS-plus-imaging economics.

Broad incumbents

  • Aidoc: Broader-scope clinical AI platform covering CT, X-ray, and other modalities with hospital-wide workflow integration. A broader incumbent in radiology AI rather than a breast/ultrasound specialist, but increasingly competing for the same enterprise imaging budgets.
  • Hologic: Major women's health imaging incumbent (mammography, ultrasound) with growing AI investments (e.g., Genius AI for DBT). Both a potential partner and competitor to Koios in breast imaging decision support, with substantially larger sales reach.
  • Philips: Koios's largest OEM partner via the Elevate Plus integration on EPIQ Elite and Affiniti ultrasound. Also a broad incumbent in ultrasound imaging that could in-source competing AI capabilities over time, making it both a channel partner and a strategic risk.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Koios Medical compliance and trust

Trust signal

Compliance3 records

Koios Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Koios Medical leadership team

Management profile

Number of profiles

Profiles3 records

Koios Medical funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Koios Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Koios Medical

What does Koios Medical do?

Koios Medical develops and sells Koios DS, an FDA-cleared and CE-marked AI-powered clinical decision support software for breast and thyroid cancer diagnosis using ultrasound images. The software analyzes over 17,000 features per image using ensemble deep learning algorithms trained on more than 500,000 proprietary ultrasound images, aligning outputs to BI-RADS (breast) and TI-RADS/ATA (thyroid) standards. The product is licensed to radiologists, hospitals, and radiology practices through annual subscription agreements and is also embedded directly into Philips and GE Healthcare ultrasound systems.

Is Koios Medical a public or private company?

Koios Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Koios Medical founded?

Koios Medical was founded in 2011. It employs 11 to 50 people.

Where is Koios Medical based?

Koios Medical is headquartered in New York, United States, in the North America region.

How does Koios Medical make money?

Two revenue lines are on record. Software License (Annual/Subscription) is the primary driver. The others are billable Procedure (CPT Codes).

Who are Koios Medical's main competitors?

Direct peers on record are Lunit, iCAD, Volpara Health Technologies, ScreenPoint Medical, Therapixel, Viz.ai and HeartFlow. Broad incumbents are Aidoc, Hologic and Philips.

Does Koios Medical have an API?

No public API is recorded for Koios Medical.

What industry is Koios Medical in?

Koios Medical's product category is AI Clinical Decision Support Software for Medical Imaging. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 3345.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooZoraida Estela JovéDr. Zoraida Estela Jové co-founded Senos Puerto Rico, a mobile breast-imaging center, and later opened Imágenes Puerto Rico. She introduced tomosynthesis-guided biopsies and ABUS, and in November 2025, her center became the first in Puerto Rico to use Koios Medical's SmartUltrasound AI for breast and thyroid nodules.Diagnostic ImagingCan Breast Ultrasound AI Offer Comparable Sensitivity to Radiologists in Pregnant and Lactating Women?A retrospective study published in European Radiology evaluated Koios DS AI ultrasound software (version 3.7.0, Koios Medical) on 639 breast ultrasound findings from 504 pregnant and lactating women, finding both AI and radiologists achieved 80% sensitivity for cancer detection, though the AI recommended biopsies for benign lesions at a 16% higher rate (37.1% vs. 21%). When galactoceles, fluid collections, and skin lesions were excluded from sub-analysis, AI performance improved with similar biopsy recommendation rates to radiologists (27.4% vs. 23.8%) and 20% greater identification of BI-RADS 2 presentations, suggesting the AI's training data lacks pregnancy- and lactation-specific entities.Towards HealthcareAI in Breast Imaging Market Increases to $844.52 Mn by 2034The global AI in breast imaging market is projected to grow from USD 509.58 million in 2024 to USD 844.52 million by 2034, with a compound annual growth rate of 3.30%, driven by rising breast cancer prevalence and technological advancements. In April 2025, RadNet, Inc. acquired iCAD, Inc. for $103 million, combining RadNet's network of over 1,500 healthcare locations handling 8 million mammograms annually with iCAD's AI-driven breast health solutions. Key market trends include strategic collaborations such as iCAD's partnership with Koios Medical, SimonMed Imaging's partnership with Lunit, and Hologic's partnership with Bayer, alongside favorable government initiatives like the UK government's £11 million EDITH trial for AI breast cancer detection.MorningstarRamSoft Partners with Koios Medical to Provide Integrated AI-Powered Software for Breast and Thyroid Cancer DiagnosisRamSoft announced a distributorship with Koios Medical to integrate Koios' AI-powered breast and thyroid cancer diagnosis software into its cloud-based RIS/PACS platforms. The software analyzes 17,900 features per image and claims up to 30% more patients per day and 49% less interpretation time. The partnership expands RamSoft's Women's Health portfolio with AI tools.PR NewswireRamSoft Partners with Koios Medical to Provide Integrated AI-Powered Software for Breast and Thyroid Cancer DiagnosisRamSoft Inc. announced a distributorship agreement with Koios Medical to integrate Koios' AI-powered Smart Ultrasound software into RamSoft's cloud-based RIS/PACS platforms. This partnership enables RamSoft customers to access Koios' FDA-cleared diagnostic tools for breast and thyroid cancer detection, which reportedly improves workflow efficiency and reimbursement eligibility. The integration expands RamSoft's existing portfolio of AI applications in women's health.Health ExecML’s Role in Building Confidence and Value in Breast ImagingMain Street Radiology in Queens, New York, has implemented Koios Medical's machine learning software to enhance the accuracy and efficiency of breast ultrasound imaging. Clinical studies indicate that this technology improves diagnostic sensitivity and specificity while significantly reducing unnecessary benign biopsies.AppliedradiologyThe Current Scope of Artificial Intelligence in Breast USThis April 2025 review article surveys four AI tools currently available or in development for breast ultrasound imaging: Koios Decision Support (FDA-cleared), See-Mode, Samsung's S-Detect, and BU-CAD by TaiHao Medical. The article examines clinical performance data, noting that these tools improve lesion detection and characterization while reducing false-positive rates and inter-observer variability, though their effectiveness varies by radiologist experience. The FDA's September 2024 mandate requiring breast density notifications for mammography patients is driving increased demand for supplemental screening, creating expanded opportunities for AI-assisted breast ultrasound.GlobeNewswireKoios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025iCAD and Koios Medical announced a strategic reseller partnership to integrate iCAD's ProFound AI mammography suite with Koios SmartUltrasound for breast cancer detection. The collaboration aims to provide radiologists with an AI-powered pathway from screening to diagnosis, targeting women with dense breast tissue. The companies will showcase the solution at ECR 2025 in Vienna.GlobeNewswireKoios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025iCAD and Koios Medical announced a reseller partnership to integrate iCAD's ProFound AI mammography suite with Koios SmartUltrasound for breast cancer detection. The collaboration aims to provide an end-to-end AI pathway for radiologists, with both companies attending ECR 2025 in Vienna.SecSEC FORM DKoios Medical, Inc. filed a Form D with the SEC for an exempt offering of securities under Rule 506(b). The company has raised $170,000 out of a total target offering amount of $500,000 from four investors as of May 2024.